Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience – A Multicenter Retrospective Study | Citedby Results | Oncology | Karger Publishers

Skip to Main Content

Skip Nav Destination

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience – A Multicenter Retrospective Study

Oncology (2022) 100 (12): 666–673.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Efficacy of eribulin monotherapy for bone marrow carcinomatosis of breast cancer in a patient with Werner syndrome

Akihito Fujimi
Yasuhiro Nagamachi
Naofumi Yamauchi
Riku Hasebe
Naoki Onoyama
Naotaka Hayasaka
Teppei Matsuno
Kazuhiko Koike
Yoshiro Gotoh
Kohji Ihara
Junji Kato
Takuji Nishisato
Kazuyuki Murase
Goro Kutomi
Tokimasa Hida
Hisashi Uhara
Kohichi Takada

Geriatrics & Gerontology International (2025) 25 (2): 316.

Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study

J. Passildas
MJ Paillard
L. Uwer
I. Molnar
N. Dohollou
T. Petit
N. Hajjaji
L. Boudin
V. Lorgis
JP Jacquin
C. Abrial
MA Mouret-Reynier

Cancer Epidemiology (2025) 96: 102800.

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes

Lan Chen
Xi Yan
Ting Luo
Tinglun Tian
Ping He
Xiaorong Zhong

Cancer Medicine (2024) 13 (10)